Genetic testing for predisposition to hypertrophic cardiomyopathy may be considered medically necessary for individuals who are at risk for development of hypertrophic cardiomyopathy, defined as having a first-degree relative with established hypertrophic cardiomyopathy, when there is a known pathogenic gene variant present in that affected relative (see Policy Guidelines section).
Genetic testing for predisposition to hypertrophic cardiomyopathy is considered investigational for individuals with a family history of hypertrophic cardiomyopathy in which a first-degree relative with established hypertrophic cardiomyopathy has tested negative for pathogenic variants.
Genetic testing for predisposition to hypertrophic cardiomyopathy is considered investigational for all other patient populations, including but not limited to individuals who have a first-degree relative with clinical hypertrophic cardiomyopathy, but in whom genetic testing is unavailable.
